Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sofinnova Investments is a healthcare investment firm founded in 1976 and headquartered in Menlo Park, California. The firm has approximately $3.3 billion in assets under management, focusing primarily on life science investing, particularly in therapeutic drugs. Over the years, Sofinnova has established itself as a key player in the biotech investment landscape, emphasizing partnerships with entrepreneurs to innovate and improve healthcare outcomes.
Since its inception, Sofinnova has evolved significantly, particularly after the restructuring of the global Sofinnova organization in 1997 into separate management companies. This profile covers the U.S.-based Sofinnova Investments, which has a strong emphasis on therapeutic innovation. The firm has funded 118 companies, resulting in 55 IPOs and 30 mergers and acquisitions, showcasing its successful track record in the biotech sector.
With a dedicated team of professionals, Sofinnova Investments operates across North America and Europe, focusing on late preclinical and clinical therapeutic companies. The firm’s commitment to company building and regulatory navigation has made it a sought-after partner for entrepreneurs in the life sciences.
Sofinnova Investments targets late preclinical and clinical therapeutic companies, primarily in North America and Europe. The firm invests across various stages, including pre-seed, seed, Series A, Series B, Series C, Series D, Series E, growth equity, and IPO. Key therapeutic areas of focus include oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. This strategic focus allows Sofinnova to support entrepreneurs in bringing innovative therapies to market.
The firm seeks to partner with life-science entrepreneurs who can drive therapeutic innovation. Sofinnova emphasizes the importance of a clear unmet medical need and a viable path through regulatory and capital-markets milestones. Their investment strategy is hands-on, providing not only financial capital but also strategic guidance in drug development, regulatory navigation, and IPO preparation.
While Sofinnova is open to various stages of investment, it is particularly interested in companies with credible late-preclinical or clinical therapeutic assets. The firm does not typically invest in broad digital health, services, consumer, or enterprise software unless they are directly tied to therapeutic platforms that align with its focus areas.
Sofinnova Investments has funded a total of 118 companies, achieving significant milestones in the biotech sector. The firm has facilitated 55 IPOs and 30 mergers and acquisitions, demonstrating its effectiveness in nurturing companies through critical growth phases. Notable portfolio companies include:
These companies exemplify Sofinnova's commitment to supporting innovative therapeutic solutions that address significant healthcare challenges.
Jim Healy, MD, PhD - Managing Partner. Jim has extensive experience in the biotech sector and has led numerous successful investments in therapeutic companies.
Maha Katabi, PhD, CFA - General Partner. Maha brings a strong analytical background and has been involved in various successful funding rounds.
David Kabakoff, PhD - Executive Partner, Private Equity. David has a deep understanding of the biotech landscape and has played a key role in several portfolio companies.
Lars Ekman, MD, PhD - Executive Partner, Private Equity. Lars has a wealth of experience in drug development and regulatory affairs.
Perry Nisen, MD, PhD - Executive Advisor, Private Equity. Perry provides strategic insights based on his extensive background in healthcare.
Jonathan Leff, MD - Executive Partner, Private Equity. Jonathan has a strong track record in managing investments in the life sciences sector.
Chris Carpenter, MD, PhD - Executive Partner, Private Equity. Chris specializes in therapeutic innovation and has been instrumental in guiding portfolio companies.
Jakob Dupont, MD - Executive Partner, Private Equity. Jakob has significant experience in clinical development and regulatory strategy.
Maha Radhakrishnan, MD - Executive Partner, Private Equity. Maha focuses on strategic investments in therapeutic companies.
Troy Ignelzi - Executive Advisor, Private Equity. Troy provides valuable insights into market trends and investment strategies.
Mike Van, PhD - Associate, Private Equity. Mike supports the investment team with research and analysis.
Naomi Pacalin, PhD - Associate, Private Equity. Naomi assists in evaluating potential investments and conducting due diligence.
Eric Hsu, PhD - Analyst, Private Equity. Eric focuses on market analysis and investment opportunities.
Nathalie Auber - Partner & CFO. Nathalie oversees financial operations and strategic planning.
Eric Delbridge, MD - General Partner, Public Equity. Eric has a strong background in public market investments.
Aneal Tenjarla - Partner, Associate Portfolio Manager, Public Equity. Aneal manages public equity investments and portfolio strategies.
Raymond Bower, MD - Portfolio Manager, Synergy Fund. Raymond focuses on managing investments in therapeutic companies.
To pitch Sofinnova Investments, founders should ideally secure a warm introduction through mutual connections in the healthcare or venture capital sectors. The pitch deck should include a clear overview of the business model, market opportunity, competitive landscape, and therapeutic innovation.
Response times can vary, but founders should expect to hear back within a few weeks after submitting their materials. Sofinnova appreciates thorough and well-prepared presentations that demonstrate a deep understanding of the therapeutic landscape.
On January 12-14, 2026, Sofinnova Investments will participate in the Biotech Showcase in San Francisco, CA, highlighting its commitment to engaging with the biotech community.
From February 3-5, 2026, the firm will also be present at the OBIO Investment Summit in Toronto, ON, further showcasing its active involvement in industry events.
Additionally, Sofinnova is scheduled to attend the Fierce Biotech Summit on September 19, 2026, in Boston, MA, indicating ongoing engagement with key stakeholders in the biotech sector.
What are Sofinnova Investments' investment criteria?
Sofinnova Investments focuses on late preclinical and clinical therapeutic companies in North America and Europe. The firm seeks to invest in key therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology, and women's health. They look for credible teams with a clear unmet medical need and a viable path through regulatory and capital-markets milestones.
How can I pitch to Sofinnova Investments?
Founders interested in pitching to Sofinnova should prepare a detailed presentation that outlines their therapeutic innovation, market potential, and regulatory strategy. While specific submission processes are not disclosed, a warm introduction through industry connections may enhance the chances of engagement.
What makes Sofinnova Investments different from other VCs?
Sofinnova Investments distinguishes itself through its deep focus on life sciences and therapeutic drug development. The firm emphasizes a hands-on approach, providing not only capital but also strategic guidance in drug development and regulatory navigation, which is critical for success in the biotech sector.
What is the geographic scope of Sofinnova Investments?
The firm primarily invests in companies located in North America and Europe, allowing it to leverage its expertise and network in these regions to support portfolio companies effectively.
What is the typical check size for investments?
While specific check sizes are not disclosed, Sofinnova Investments invests across various stages, from pre-seed to IPO, indicating a flexible approach to funding based on the needs of the portfolio companies.
What kind of post-investment support does Sofinnova provide?
Sofinnova Investments offers extensive post-investment support, including strategic guidance in drug development, regulatory navigation, and preparation for IPOs. The firm actively participates in the growth of its portfolio companies, ensuring they achieve their milestones.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.